FDA Approves New Treatment for People With Plaque Psoriasis

The U.S. Food and Drug Administration (FDA) approved Zoryve (roflumilast) cream 0.3 percent for the treatment of plaque psoriasis, including intertriginous areas (where skin rubs against other skin) in people 12 years of age and older, according to a press release issued by Arcutis, the manufacturer of the drug. Once-daily Zoryve is the first and only approved topical phosphodiesterase-4 (PDE4) inhibitor, the first and only FDA-approved steroid-free cream in its class.

PDE4 inhibitors suppress the immune system by reducing the action of an overactive enzyme (phosphodiesterase 4), thereby reducing inflammation.

“It is always great to have another topical option to treat psoriasis, so this approval is exciting,” says Marisa Garshick, MD, a board-certified dermatologist at MDCS Dermatology in New York City. Zoryve will be a good choice for those patients who prefer to avoid a topical steroid, she adds.

This approval offers yet another steroid-free option for people with plaque psoriasis; in May, the FDA approved Vtama (tapinarof) cream 1 percent for topical treatment of mild, moderate, or severe plaque psoriasis in adults.

Source link

Leave A Reply

Your email address will not be published.